Related Experiment Videos
Doxorubicin clearance in the obese
K A Rodvold1, D A Rushing, D A Tewksbury
1Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago 60612.
Summary
Obesity significantly impacts doxorubicin pharmacokinetics, affecting drug clearance and half-life. This highlights the need to consider patient weight in cancer treatment analysis for toxicity and response.
Area of Science:
- Pharmacology
- Oncology
- Clinical Pharmacy
Background:
- Obesity is a growing concern in patient populations undergoing cancer treatment.
- The influence of body mass on the pharmacokinetic profile of chemotherapeutic agents like doxorubicin requires thorough investigation.
Purpose of the Study:
- To investigate the relationship between obesity and the pharmacokinetics of doxorubicin.
- To determine if obesity affects doxorubicin clearance, half-life, and volume of distribution.
Main Methods:
- A study involving 21 patients receiving their first course of doxorubicin.
- Patients were stratified into normal, mildly obese, and obese groups based on ideal body weight percentage.
- Doxorubicin and doxorubicinol levels were quantified using high-performance liquid chromatography.
Main Results:
- Doxorubicin clearance was significantly reduced in obese patients (P < .001).
- The elimination half-life of doxorubicin was prolonged in obese patients (20.4 hours vs. 13.0 hours in normal patients).
- Area under the curve (AUC) for doxorubicin was higher in obese patients, indicating increased drug exposure.
Conclusions:
- Obesity significantly alters doxorubicin pharmacokinetics, primarily by reducing its clearance.
- These pharmacokinetic changes in obese patients may influence doxorubicin toxicity and therapeutic efficacy.
- Clinical data analysis for antineoplastic agents should account for obesity's impact on drug disposition.